PT - JOURNAL ARTICLE AU - Sarah Tubiana AU - Charles Burdet AU - Nadhira Houhou AU - Michael Thy AU - Pauline Manchon AU - François Blanquart AU - Charlotte Charpentier AU - Jérémie Guedj AU - Loubna Alavoine AU - Sylvie Behillil AU - Anne Leclercq AU - Jean-Christophe Lucet AU - Yazdan Yazdanpanah AU - Mikaël Attia AU - Caroline Demeret AU - Thierry Rose AU - Julia Anna Bielicki AU - Patricia Bruijning-Verhagen AU - Herman Goossens AU - Diane Descamps AU - Sylvie van der Werf AU - Bruno Lina AU - Xavier Duval TI - High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in healthcare workers: results of the CoV-CONTACT prospective cohort AID - 10.1101/2020.09.17.20194860 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.17.20194860 4099 - http://medrxiv.org/content/early/2020/09/18/2020.09.17.20194860.short 4100 - http://medrxiv.org/content/early/2020/09/18/2020.09.17.20194860.full AB - Objective We aimed to estimate the risk of infection in Healthcare workers (HCWs) following a high-risk exposure without personal protective equipment (PPE).Methods We conducted a prospective cohort in HCWs who had a high-risk exposure to SARS-CoV-2-infected subject without PPE. Daily symptoms were self-reported for 30 days, nasopharyngeal swabs for SARS-CoV-2 RT-PCR were performed at inclusion and at days 3, 5, 7 and 12, SARS-CoV-2 serology was assessed at inclusion and at day 30. Confirmed infection was defined by positive RT-PCR or seroconversion, and possible infection by one general and one specific symptom for two consecutive days.Results Between February 5th and May 30th, 2020, 154 HCWs were enrolled within 14 days following one high-risk exposure to either a hospital patient (70/154; 46.1%) and/or a colleague (95/154; 62.5%). At day 30, 25.0% had a confirmed infection (37/148; 95%CI, 18.4%; 32.9%), and 43.9% (65/148; 95%CI, 35.9%; 52.3%) had a confirmed or possible infection. Factors independently associated with confirmed or possible SARS-CoV-2 infection were being a pharmacist or administrative assistant rather than being from medical staff (adjusted OR (aOR)=3.8, CI95%=1.3;11.2, p=0.01), and exposure to a SARS-CoV-2-infected patient rather than exposure to a SARS-CoV-2-infected colleague (aOR=2.6, CI95%=1.2;5.9, p=0.02). Among the 26 HCWs with a SARS-CoV-2-positive nasopharyngeal swab, 7 (26.9%) had no symptom at the time of the RT-PCR positivity.Conclusions The proportion of HCWs with confirmed or possible SARS-CoV-2 infection was high. There were less occurrences of high-risk exposure with patients than with colleagues, but those were associated with an increased risk of infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04259892Funding StatementThe study was founded by Reacting, the French Ministry of Health (PHRC-N COVID-19, project PHRC-20-0242) and the European Commission (RECoVer, grant agreement 101003589). Some authors received financial support of the national research agency (ANR) through the ANR-Flash calls for COVID-19 (TheraCoV ANR-20-COVI-0018)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the French National Data Protection Commission (approval #920102), and the French Ethics committee (CPP-Ile-de-France-6, #2020-A00280-39) and all subjects provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing will be considered upon request.